Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Interleukin-11 inhibitor

EU flag

Boehringer’s Giotrif wins new NSCLC licence in Europe

Can now be marketed for advanced squamous cell carcinoma of the lung

- PMLiVE

Gilead boosts liver disease pipeline with $1.2bn acquisition

Also has combination HIV therapy Descovy approved by FDA

- PMLiVE

AbbVie pays $595m upfront for Boehringer psoriasis drug

Says BI 655066 has the potential to become a ‘best-in-class’ treatment

- PMLiVE

Boehringer Ingelheim on walking the talk in patient-centricity

UK medical director Professor Klaus Dugi on patient engagement

- PMLiVE

Boehringer plans €500m biopharma expansion in Austria

New production facility in Vienna will create 400 jobs when it comes online in 2021

Sanofi reception

Sanofi and Boehringer in $20bn asset swap negotiations

Want to exchange their consumer health and veterinary interests

- PMLiVE

Boehringer’s coughing beat box drives its message home

Throat hacking performance raises awareness of lung cancer symptom

Boehringer Ingelheim headquarters

Boehringer pledges €11bn to fund R&D drive

Plans more external collaborations as it appears to reduce spending

- PMLiVE

Boehringer appoints new chairman of the board

Hubertus vonBaumbach will succeed Andreas Barner

- PMLiVE

Boehringer takes third-generation NSCLC drug into pivotal trials

Startsphase II study of BI 1482694 in patients who test positive for T790M mutation

- PMLiVE

Boehringer’s Praxbind granted accelerated approved by FDA

Reversal agent for anticoagulant Pradaxa given the nod

Boehringer Ingelheim headquarters

Boehringer and Philogen collaborate on acute myeloid leukaemia

Hope to bring new therapies for the rare disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links